Abstract: The invention provides monoclonal antibodies and other binding agents to human cytochrome P450 2A6 having advantageous properties, including capacity substantially to inhibit enzyme activity of human cytochrome P450 2A6 and lack of specific binding to other human cytochromes P450. The binding agents of the invention are useful inter alia in methods for screening drugs for metabolism by cytochrome P450 2A6, and in methods of measuring p450 2A6 levels in an individual relative to p450 2A6 levels in a control population.

Abstract: A novel gene designated as FRAG 1 and its encoded protein are disclosed. A fusion protein called FGFR2-ROS, which is formed by chromosomal rearrangement of rat FRAG1 with FGFR2, is also disclosed. Methods of producing FRAG1 protein, related fusion proteins, and antibodies against FRAG1 are disclosed, as are related pharmaceuticals and methods of using such nucleic acids, polypeptides, and antibodies.

Abstract: This invention relates to compositions and methods useful for activating LT-&bgr; receptor signaling, which in turn elicits potent anti-proliferative effects on tumor cells. More particularly, this invention relates to lymphotoxin heteromeric complexes formed between lymphotoxin-&agr; and multiple subunits of lymphotoxin-&bgr;, which induce cytotoxic effects on tumor cells in the presence of lymphotoxin-&bgr; receptor activating agents. Also within the scope of this invention are antibodies directed against the lymphotoxin-&bgr; receptor which act as lymphotoxin-&bgr; receptor activating agents alone or in combination with other lymphotoxin-&bgr; receptor activating agents either in the presence or absence of lymphotoxin-&agr;/&bgr; complexes. A screening method for selecting such antibodies is provided.

Abstract: Described is a monoclonal antibody capable of specifically binding to fibroblast growth factor-8 (FGF-8) which is related to growth factors of hormone-dependent tumor cells such as prostatic cancer and breast cancer, and inhibits the FGF-8 activity. The monoclonal antibody is useful in analyzing the role and biological function of FGF-8 in hormone-dependent tumor cells such as prostatic cancer and breast cancer and can be beneficial in the treatment of these cancers.

Abstract: The present invention provides a purified antibody which specifically reacts with human histidine decarboxylase (HDC), as well as immunogenic compositions comprising HDC peptides.

Abstract: Monoclonal antibodies with specificity for membrane-associated antigens and methods of using them in detection of tumor-associated antigens arc described.

Abstract: Antibodies, as well as binding fragments and mimetics thereof, that specifically bind to polyglutamine expansion containing proteins, e.g. mutant huntingtin protein, are provided. The subject binding agents, e.g. antibodies, fragments and mimetics thereof, etc., are characterized in that they bind to the target polyglutamine expansion containing protein in a manner that differs from the 1C2 antibody, e.g. in terms of affinity, avidity, and the like. Also provided are methods of screening compounds for polyglutamine expansion protein binding modulation activity, as well as pharmaceutical compositions of such agents. In addition, methods and devices for screening samples for the presence of polyglutamine expansion containing proteins, e.g. mutant huntingtin protein, are provided. Finally, nucleic acids encoding the subject antibodies and methods for their expression, including in therapeutic treatment protocols, are provided.

Abstract: The invention provides methods for inhibiting the growth of a cell bearing a LewisY antigen. The methods involve contacting the cell with a composition comprising an Fv region of a light chain of a monoclonal antibody selected from B1, B3, and B5, and the Fv region of a humanized heavy chain of a monoclonal antibody independently selected from B1, B3, and B5, provided that if the heavy and the light chains are from the same antibody, the residue at position 95 of the heavy chain is a serine, and, if the antibody chain is from B3, the residue at position 4 of the light chain can be a leucine and the residue at position 82b of the heavy chain can be an arginine. The Fv regions are joined to an effector molecule selected from a chemotherapeutic agent, a toxin, a radioisotope, and a liposome loaded with a chemotherapeutic agent. In preferred embodiments, the heavy chain and the light chain are recombinantly fused, and the Fv regions are recombinantly fused to a toxin.

Abstract: The invention features a monoclonal antibodies specific for human type I alveolar cells or for human type II alveolar cells. The invention also features methods of detecting lung injury in a subject using these monoclonal antibodies.

Abstract: Nuclear matrix proteins (NMP) which are characterized by a defined expression in bladder tissue are provided, which can be used to generate antibodies that differentiate between normal and cancerous bladder tissue. These NMPs are useful markers in diagnosing and monitoring the stage of malignancy of a bladder cell and treating bladder cell proliferative disorders associated with the NMP. Also provided are substantially purified polypeptides and nucleotide sequences encoding the NMPs of the invention.

Abstract: An anti-KC-4 humanized monoclonal antibody that comprises the variable regions of the light and heavy chains of the anti-KC-4 murine antibody, wherein the light chain has 7 amino acids and the heavy chain has 12 amino acids of the framework regions substituted with amino acid present in equivalent positions in antibodies of a species other than munne, and the constant regions of a human antibody. The antibody may be labeled and/or glycosylated, and is presented as a composition with a carrier. The anti-KC-4 monoclonal antibody is used in diagnostic kits for cancer and in in vivo methods of imaging and treating a primary or metastasized cancer, and in vitro diagnosis and ex vivo purging neoplastic cells from a biological fluid. RNAs and DNAs encode the monoclonal antibody, and a hybrid vector carrying the nucleotides and transfected cells express the peptides.

Abstract: An anti-CEA monoclonal antibody, designated 806.077, of murine origin is useful for the diagnosis and therapy of cancer. The antibody complementarity determining regions have the following sequences: heavy chain CDR1 DNYMH, CDR2 WIDPENGDTE YAPKFRG, CDR3 LIYAGYLAMD Y; and light chain CDR1 SASSSVTYMH, CDR2 STSNLAS, CDR3 QQRSTYPLT. The antibody optionally is humanized and can be in the form of a conjugate with either an enzyme, such as carboxypeptidase, or a co-stimulatory molecule such as the extracellular domain of human B7.1.

Abstract: The present invention provides methods for inhibiting the growth of prostate tumor cells expressing Prostate Stem Cell Antigen (PSCA), the methods comprising administering to a patient a monoclonal antibody which binds specifically to the extracellular domain of PSCA in an amount effective to inhibit growth of the prostate tumor cells.

Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, bladder cancer and bone metastasis of prostate cancer. Antibodies specific to PSCA are used for diagnosis of these cancers.

Abstract: The invention provides methods for detecting the presence of a PSCA protein comprising contacting the sample with PSCA antibodies designated 1G8 (ATCC No. HB-12612), 2A2 (ATCC No. HB-12613), 2H9 (ATCC No. HB-12614), 3C5 (ATCC No. HB-12616), 3E6 (ATCC No. HB12618), 3G3 (ATCC No. HB-12615), or 4A10 (ATCC No. HB-12617).

Abstract: The invention provides a novel prostate cell-surface antigen, designated Prostate Stem Cell Antigen (PSCA), which is widely over-expressed across all stages of prostate cancer, including high grade prostatic intraepithelial neoplasia (PIN), androgen-dependent and androgen-independent prostate tumors.

Abstract: The present invention relates to stabilized compositions of troponin capable of serving as standard and/or control in immunoassays intended for assaying cardiac and/or skeletal troponin(s) in the blood serum or blood plasma of humans or animals. These stabilized compositions comprise, in aqueous solution, troponin I, troponin T and troponin C in the form of an I-T-C ternary complex.

Abstract: Methods for treating and inhibiting disease and symptoms associated with the human immunodeficiency virus (HIV) are provided. The method includes transforming the human immunodeficiency virus (HIV) infection into a nonserious disease through the infusion of monoclonal antibodies directed against particular antigens on anti-self, anti-CD4 cytotoxic T-lymphocytes. The monoclonal antibodies are primarily directed against the alpha or beta chain of LFA-1.

Abstract: A humanized specific monoclonal antibody or antibody fragment, especially a B-cell specific antibody or antibody fragment, is engineered to contain a glyxosylation site in the non-Fc constant region. The glycosylated antibody is useful for diagnosis and/or therapy whenever a targeting antibody or fragment is used, especially for B-cell malignancies. The carbohydrate moiety allows conjugation of labeling or therapeutic agents of increased size, without affecting the binding affinity or specificity of the antibody.

Abstract: The invention relates to antibodies which bind to the cancer associated antigen NY-ESO-1. Both polyclonal and monoclonal antibodies are part of the invention, as are chimeric forms of the antibodies, and binding portions of antibodies. Uses of these antibodies are described. Also described are truncated, recombinant forms of the cancer associated antigen.

Abstract: A method of modulating angiogenesis in a vertebrate subject, the method comprising administering to the vertebrate subject an ECRTP/DEP-1 receptor activity-modulating amount of a composition, whereby an ECRTP/DEP-1 receptor within the vertebrate subject is contacted by the composition; and modulating angiogenesis through the contacting of the ECRTP/DEP-1 receptor with the composition. Optionally, the composition includes a monoclonal antibody which preferentially binds the ECRTP/DEP-1 receptor.

Abstract: This invention provides tumor metastasis-inhibiting monoclonal antibodies, mAb 41-2, mAb 50-6 and mAb 1A-5. The antigen recognized by mAb 50-6 and mAb 1A-5 has been identified as the PETA-3 antigen. The antigen recognized by mAb 41-2 has been identified as a novel tumor metastasis-associated antigen. Compositions and methods are provided that are useful for treating and diagnosing metastatic tumors.

Abstract: The DNA sequence spanning the fragile X site on the X human chromosome has been obtained in purified and isolated form. As fragile X is associated with mental retardation, the availability of a DNA which spans this locus permits diagnosis and treatment of the related mental disorders. Polyclonal and monoclonal antibodies to an amino acid sequence encoded by SEQ ID NO:1, a DNA sequence from the Fragile X site, are also disclosed.

Abstract: The subject invention provides an isolated protein having an apparent molecular weight of about 27 kD and capable of binding to and inhibiting the activation of a cyclin E-Cdk2 complex. The subject invention further provides an isolated antibody and a purified preparation of polyclonal and monoclonal antibodies which are specifically immunoreactive with a p27 protein. The subject invention further provides a kit for detecting a p27 protein.

Abstract: A bispecific antibody has binding specificity for a marker common to all prostate cells on one arm of the antibody, and binding specificity for T cell marker CD3 on the other antibody arm. The combined specificities bring together a tumor cell and a T effector cell, whose specificity is reprogrammed to kill the tumor cell. Invitro studies showed that the bispecific antibody achieves a much greater level of cytotoxicity than either individual antibody alone.

Abstract: Monoclonal antibodies against dihydropyrimidine dehydrogenase are disclosed. Immunologic assays using the monoclonal antibodies are also disclosed.

Abstract: The present invention provides a method for targeting boron atoms to tumor cells in a patient. The method includes the steps of (A) administering a targeting composition comprising a conjugate of (i) at least one first antibody or antigen-binding antibody fragment which selectively binds to an antigen produced by or associated with the tumor cells and present at the tumor cells, and (ii) at least one second antibody or antibody fragment which specifically binds to a hapten on a boron compound; (B) optionally, a clearing composition; (C) said boron compound; and (D) optionally, a second clearing composition. The method may further comprise the step of irradiating the boron atoms of the boron compound, thereby effecting BNCT of the tumor cells. Compositions and kits for carrying out the method also are provided.

Abstract: The invention provides for the production of several humanized murine antibodies specific for the antigen FB5, which is recognized by the murine antibody FB5. The FB5 antigen is expressed on the luminal surface of vascular endothelial cells of a wide range of malignant tumors. The invention also provides for numerous polynucleotide encoding humanized FB5 specific antibodies, expression vectors for producing humanized FB5 specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized FB5 specific antibodies. Additionally, the invention provides methods of treating cancer using FB5 specific antibodies.

Abstract: Hybridoma cell lines producing monoclonal antibodies specific to the human epidermal growth factor receptor are disclosed. The antibodies are capable of inhibiting the growth of human tumor cells expressing human epidermal growth factor receptors. Therapeutic uses of these monoclonal antibodies by themselves and in combination with anti-neoplastic agents are also disclosed.

Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.

Abstract: The present invention discloses a procedure for the destruction of contaminating tumor cells in stem cell transplants ex vivo using intact bispecific antibodies.

Abstract: Disclosed is an antibody that binds to a protein found on normal and cancerous prostate cells, but not found on nonprostate cells and a hybridoma that produces the antibody to the prostate-specific protein. Also disclosed are antibodies conjugated to labels or cytotoxic moieties.

Abstract: Hepatocyte growth factor (HGF) receptor antagonists are provided. The HGF receptor antagonists include HGF receptor antibodies and fragments thereof. The HGF receptor antagonists can be employed to block binding of HGF to HGF receptors or substantially inhibit HGF receptor activation. The HGF receptor antagonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treating cancer using the HGF receptor antagonists are also provided.

Abstract: The present invention is directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and epithelial cell marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer. The present invention is also directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and tumor associated marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer.

Abstract: Measurements of elevated levels of riboflavin carrier protein (RCP) can be used to detect breast, liver, ovarian, and endometrial cancers. Stains for riboflavin carrier protein can be used to visualize malignancies in tissue specimens. The new technique is particularly well-suited for the early detection of breast cancer. With a radioimmunoassay for RCP, we have observed that serum RCP levels were significantly elevated in women with breast cancer as compared to control subjects. A serum RCP level ≧1.0 ng/ml was highly predictive of the presence of breast cancer (other than in pregnant females).

Abstract: A monoclonal antibody which is specific to a polypeptide having a molecular weight of 18, 500±3,000 daltons on SDS-PAGE and a pI of 4.9±1.0 on chromatofocusing. The monoclonal antibody is obtainable from hybridomas and can be used for the purification and detection of the polypeptide. The polypeptide strongly induces the IFN-&ggr; production by immunocompetent cells with only a small amount, and does not cause serious side effects even when administered to human in a relatively-high dose.

Abstract: A method of neutralizing TNF&agr; in a patient benefiting from such neutralizing, comprising administering to the patient IgG Fab fragment reactive towards TNF&agr;. Suitably, the patient is suffering from septic shock or from the symptoms of septic shock. It is preferred if the Fab fragment is derived from polyclonal IgG.

Abstract: Monoclonal antibodies and method for ameliorating an immune response disorder. The monoclonal antibodies are specific for an epitope present on the leukocyte adhesion receptor &bgr;-chain.

Abstract: The presence of A-protein in an abnormally large amount in a sample, such as blood, from an individual is diagnostic of primary or metastatic cancer in the individual. The presence of A-protein is most readily detected by immunological reaction of it with specific antibodies. A preferred procedure for detecting the presence of A-protein in samples is by a sandwich assay using two antibodies with different epitopic specificities for A-protein.

Abstract: A variety of heparanase specific molecular probes which can be used for research and medical applications including diagnosis and therapy. Specific applications include the use of a heparanase specific molecular probe for detection of the presence, absence or level of heparanase expression; the use of a heparanase specific molecular probe for therapy of a condition associated with expression of heparanase; the use of a heparanase specific molecular probe for quantification of heparanase in a body fluid; the use of a heparanase specific molecular probe for targeted drug delivery; and the use of a heparanase specific molecular probe as a therapeutic agent.

Abstract: A method for preparing a cocaine-protein conjugate easily by using a cocaine derivative having a methoxy carbonyl group and benzoyl group. This conjugate is useful for the detection of cocaine or cocaine derivatives. A monoclonal antibody, a monoclonal antibody producing cell line, and a method for producing the monoclonal antibody producing cell line by using the above cocaine-protein conjugate as an immunogen is also described.

Abstract: Isolated cDNA molecules which encode the tumor rejection antigen precursor MAGE-10, the protein itself, antibodies to it, and uses of these are a part of the invention.